Eli Lilly Buys Centessa for .3 Billion in Push to Dominate Sleep Disorder Market

Pharma Giant Bets on Next-Generation Wakefulness Drugs Targeting OX2R Protein

Eli Lilly is spending .3 billion to acquire London-based Centessa Pharmaceuticals, securing a portfolio of neuroscience medicines that could transform treatment of sleep disorders.

Deal Terms

• Purchase price: per share (41% premium on 30-day average)
• Additional potential: Up to per share via contingent value rights (CVRs)
• Total potential deal value: Up to .8 billion
• CVR triggers: FDA approval of either narcolepsy drug

The Science: OX2R

Centessa has two clinical-stage drugs that stimulate the OX2R brain protein, which promotes wakefulness. The OX2R mechanism is considered the next frontier in sleep medicine, with potential to treat:

• Narcolepsy
• Excessive daytime sleepiness
• Other sleep-wake disorders

Competitive Landscape

The OX2R space is hotly contested. Other companies racing to market include:

• Takeda
• Eisai
• Alkermes

Lilly buyout intensifies this competition and signals that major pharma sees massive commercial potential in sleep disorder therapeutics.

Why Now

Flush with cash from its obesity drug franchise (Mounjaro/Zepbound), and with a valuation that briefly exceeded trillion, Lilly has been an active dealmaker. This acquisition diversifies beyond metabolic disease and into neuroscience, complementing recent immune system drug acquisitions including the .2 billion Ventyx Biosciences buyout.

Source: BioPharma Dive https://www.biopharmadive.com/news/lilly-centessa-6B-dollar-buyout-sleep-narcolepsy-drug/816226/